# TechnoVax, Inc.

> TechnoVax is a small, privately held New York biotechnology company that designs noninfectious virus-like particle vaccines, licenses and collaborates around early-stage candidates, and sells research bioservices. Its long-running bet is that structural mimics of viruses can produce broad immune responses without carrying viral genetic material. Federal agencies have awarded the company roughly $10 million across nine SBIR awards, but its public pipeline remains preclinical or near-clinical, making TechnoVax a useful case study in both capital-efficient platform science and the costly gap between promising animal data and a human trial.

- **Founded:** 2003
- **Headquarters:** Elmsford, United States
- **Founders:** Jose M. Galarza (President, CEO and founder), George R. Martin (Chief Technical Officer and co-founder)
- **Team size:** 5 employees listed on LinkedIn; 6 reported by SBIR.gov
- **Products:** Universal influenza VLP vaccine, Inhaled powder VLP vaccines, Seasonal tetravalent influenza VLP vaccine, RSV VLP vaccine, Adenovirus-like particle vaccines
- **Notable:** Won nine federal SBIR awards totaling $10,022,344, with an 80% Phase I-to-Phase II conversion rate reported by SBIR.gov., Received a $2.9 million NIH award in 2009 for influenza VLP vaccine development., Received a $1.481 million NIH Phase II award in 2018 for a broadly protective influenza VLP vaccine.

## Products & services

- **Universal influenza VLP vaccine** — Preclinical VLP candidates displaying remodeled hemagglutinin proteins intended to expose conserved epitopes and broaden protection across influenza strains.
- **Inhaled powder VLP vaccines** — Shelf-stable powder formulations for pulmonary self-delivery, developed by combining TechnoVax VLPs with MannKind delivery technology; publicly described for influenza and RSV.
- **Seasonal tetravalent influenza VLP vaccine** — A multivalent VLP concept designed to combine influenza antigens in a cell-based production system.
- **RSV VLP vaccine** — Preclinical virus-like particles presenting combinations of prefusion F, postfusion F, G and SH proteins, supported by NIH Phase I awards.
- **Adenovirus-like particle vaccines** — Recombinant AdVLP candidates for respiratory adenovirus serotypes; a 2023 paper reported a potent humoral response against adenovirus-7 in animal studies.
- **Zika VLP vaccine** — A preclinical vaccine strategy published in PLOS Neglected Tropical Diseases that assembled Zika VLPs from structural and nonstructural proteins.
- **SARS-CoV-2 VLP vaccine** — A CUNY collaboration that generated and characterized SARS-CoV-2-like particles with modified stabilized spike proteins; patents were published in 2023 and 2025.
- **Bioservices** — Contract or collaborative production of recombinant proteins, antibodies, ELISA work, RSV and dengue reagents, custom VLPs, and modified Vero or MDCK cell lines.

## Achievements

- Won nine federal SBIR awards totaling $10,022,344, with an 80% Phase I-to-Phase II conversion rate reported by SBIR.gov.
- Received a $2.9 million NIH award in 2009 for influenza VLP vaccine development.
- Received a $1.481 million NIH Phase II award in 2018 for a broadly protective influenza VLP vaccine.
- Published a Zika VLP vaccine study in PLOS Neglected Tropical Diseases in 2017.
- Reported SARS-CoV-2 VLP generation and characterization with CUNY researchers in 2020.
- Published peer-reviewed adenovirus-7 VLP vaccine results in npj Vaccines in 2023.
- Secured a U.S. patent in 2020 covering universal VLP influenza vaccines; later SARS-CoV-2 VLP patent applications were published in 2023 and 2025.

## Latest updates

- **2026-06** — A supplied company record lists a $5 million debt financing; lender and terms were not disclosed in that record.
- **2025-06** — A TechnoVax-assigned SARS-CoV-2 VLP vaccine patent application was published as US20250197885.
- **2023-10** — TechnoVax and collaborators published an npj Vaccines study reporting that an adenovirus-7 VLP candidate induced a potent humoral response in animal work.
- **2023-06** — A U.S. patent application covering modified-spike SARS-CoV-2 VLP compositions and delivery methods was published.
- **2020-08** — TechnoVax and CUNY School of Medicine announced generation and characterization of SARS-CoV-2 virus-like particles.

## Links

- Website: https://www.technovax.com/
- LinkedIn: https://www.linkedin.com/company/technovax-inc.

---

Profile page: https://yespress.io/technovax-inc
Published by YesPress — https://yespress.io
Last updated: 2026-08-20